Trust Signals
Conflicts of interest: FormBlends sells peptide products. All claims are graded by evidence tier. Speculation is labeled as such.
Scope: This page covers timing, mechanism, dosing conventions, and bioavailability. It is not a substitute for medical advice.
Key Takeaways
- Morning, pre-exercise administration (roughly 30 to 60 minutes before activity) is the timing convention in preclinical MOTS-c research, though no human RCT has confirmed this is optimal.
- MOTS-c is a 16-amino-acid mitochondria-derived peptide that activates AMPK and suppresses the folate cycle under metabolic stress, the mechanism that makes exercise-adjacent timing biologically plausible.
- The foundational 2015 Lee et al. mouse study used 5 mg/kg intraperitoneal injections. Human-equivalent dosing is not established by controlled trial data.
- Oral bioavailability is essentially zero for an unmodified peptide of this class. Subcutaneous injection is the only delivery route with any evidence behind it.
- Human safety data are extremely limited. Existing clinical use is largely anecdotal or from very small pilot studies, and confidence in any specific human protocol is low.
Direct Answer: When to Take MOTS-c Peptide
The best-supported timing for MOTS-c is subcutaneous injection in the morning, 30 to 60 minutes before exercise. This mirrors the timing used in preclinical studies and aligns with MOTS-c's role in AMPK-driven metabolic signaling during physical stress. On rest days, morning administration is still conventional. No human RCT has compared timing windows head to head.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What does MOTS-c do and why does timing matter mechanistically?
- Evidence ledger: how strong is each timing claim?
- Should MOTS-c be taken before or after exercise?
- Morning vs. evening: does time of day matter?
- What dose and frequency are used in research?
- What most pages get wrong: oral vs. injection bioavailability
- Stability, reconstitution, and formulation gotchas
- Honest head-to-head: MOTS-c vs. real alternatives
- Operational guide: reading a MOTS-c COA and vial label
- FAQ
- Sources
What Does MOTS-c Do and Why Does Timing Matter Mechanistically?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S rRNA gene of mitochondrial DNA. Its sequence in humans is MRWQEMGYIFYPRKLR. It was first characterized by Lee et al. in a 2015 Cell Metabolism paper (PMID: 25738459) which showed it regulates glucose metabolism and opposes diet-induced obesity in mice.
The mechanistic chain relevant to timing:
- Metabolic stress trigger: Under glucose restriction or exercise, mitochondria release MOTS-c into the cytoplasm and then into systemic circulation.
- AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master energy-sensing enzyme, which increases GLUT4 translocation and skeletal muscle glucose uptake.
- Folate cycle suppression: The Lee 2015 paper showed MOTS-c inhibits the folate cycle and de novo purine synthesis pathway, with AICAR (an AMPK activator) accumulating as a result. This is one of the more specific mechanistic data points in the literature.
- Nuclear translocation: A 2019 paper (Kim et al., PMID: 31806877) showed that under stress, MOTS-c translocates to the nucleus and modulates stress-response gene expression, suggesting downstream effects that outlast the peptide's circulating half-life.
Why this makes timing matter: Because MOTS-c works most relevantly during states of metabolic demand (exercise, fasting), administering it when those pathways are already being recruited has a mechanistic basis. This does not prove pre-exercise dosing is superior, only that it is plausible.
Evidence Ledger: How Strong Is Each Timing Claim?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| MOTS-c activates AMPK in skeletal muscle | Mouse in vivo + cell culture (Lee 2015, Cell Metabolism) | Positive, robust in rodents | Moderate (animal) |
| Pre-exercise timing improves metabolic outcomes vs. no treatment | Mouse studies, intraperitoneal injection | Positive in mice | Low (no human trial) |
| Circulating MOTS-c rises with exercise in humans | Observational human study (Kim et al. 2019, Cell Metabolism) | Positive correlation | Moderate |
| Morning dosing is superior to evening dosing | Mechanistic reasoning only; no comparative trial | Plausible, unproven | Very Low |
| 5-days-on, 2-days-off cycling is optimal | Anecdotal clinical convention; no trial | Unknown | Very Low |
| Subcutaneous injection provides meaningful systemic exposure | Pharmacological convention for peptides of this class; assumed by all published protocols | Likely yes | Low to Moderate |
| Oral MOTS-c is ineffective | Peptide biochemistry (protease degradation); no oral human trial conducted | Expected no efficacy orally | Moderate (mechanistic) |
| MOTS-c improves insulin sensitivity in humans | One small pilot study; no large RCT | Positive signal, preliminary | Very Low |
Should MOTS-c Be Taken Before or After Exercise?
Preclinical studies consistently used pre-exercise or morning-of administration rather than post-exercise. The mechanistic logic: MOTS-c primes AMPK signaling before the exercise stimulus arrives, potentially amplifying the metabolic response rather than supplementing recovery afterward.
A 2019 Cell Metabolism paper by Kim et al. documented that endogenous MOTS-c levels rise in humans during exercise, suggesting the peptide is naturally a pre-exercise or during-exercise signal rather than a recovery molecule. Injecting exogenous MOTS-c beforehand attempts to replicate that natural rise.
Post-exercise use: There is no published evidence that post-exercise dosing is harmful or ineffective. It simply lacks any mechanistic or empirical support compared to pre-exercise. If a user cannot inject before a session, morning-of or within a few hours post-exercise remains a reasonable second choice by convention only.
Morning vs. Evening: Does Time of Day Matter?
No published study has directly compared morning versus evening MOTS-c injection in humans or animals. The morning preference comes from two indirect lines of reasoning:
- Exercise coupling: Most users train in the morning, and coupling to exercise is the primary rationale for any specific timing at all.
- AMPK circadian rhythm: AMPK activity and mitochondrial biogenesis signals show circadian oscillation in rodent models, with peak sensitivity generally in the active phase (morning in diurnal humans). This is established for AMPK generally, not specifically studied for exogenous MOTS-c.
If a user trains in the evening, evening pre-exercise dosing is equally defensible by the same mechanistic logic. There is no evidence that morning dosing independent of exercise timing is superior.
What Dose and Frequency Are Used in Research?
The clearest data come from Lee et al. 2015 (Cell Metabolism, PMID 25738459):
- Mouse dose: 5 mg/kg intraperitoneal injection, administered daily for several weeks
- Outcome: reduced body weight, improved insulin sensitivity, increased exercise capacity in diet-induced obese mice
Direct mg/kg translation from mouse to human is not valid without allometric scaling, and even scaled doses do not predict human efficacy or safety. A 5 mg/kg mouse dose allometrically converts to a much lower human equivalent (often estimated via body surface area correction at roughly one-twelfth the mg/kg value), but this is a pharmacokinetic approximation, not a clinical dose.
Published human-adjacent usage (small pilots, case series) has used subcutaneous doses ranging from approximately 5 mg to 25 mg, but no large controlled human trial has established a dose-response curve.
| Protocol Type | Dose Range | Frequency | Route | Evidence Level |
|---|---|---|---|---|
| Mouse research (Lee 2015) | 5 mg/kg | Daily | Intraperitoneal | Animal RCT |
| Clinical convention (anecdotal) | 5 to 25 mg | 5 days on, 2 off | Subcutaneous | Anecdotal/very small pilot |
| Human pilot (limited published data) | 10 to 25 mg | Variable | Subcutaneous | Very Low (small n) |
What Most Pages Get Wrong: Oral vs. Injection Bioavailability
Most commodity pages either ignore route of administration or vaguely mention "injection" without explaining why oral MOTS-c is not viable. Here is the actual chemistry.
MOTS-c is an unmodified 16-amino-acid peptide with a molecular weight of approximately 2,174 Daltons. When swallowed:
- Gastric pepsin cleaves peptide bonds at aromatic and hydrophobic residues (phenylalanine, tyrosine, tryptophan), all of which appear in MOTS-c's sequence.
- Pancreatic proteases (trypsin, chymotrypsin, elastase) continue degradation in the small intestine.
- Even fragments that survive enzymatic attack face poor transcellular transport across enterocytes at this molecular weight without active transport mechanisms.
The result is that measurable intact MOTS-c reaching systemic circulation via oral ingestion is, for all practical purposes, zero. No oral bioavailability data for MOTS-c exists, because no serious researcher has pursued it for an unmodified peptide of this class. Any product claiming oral MOTS-c activity either contains a heavily modified analog (which would need to be specified and separately tested) or is making an unsupported claim.
Subcutaneous injection deposits the peptide in the interstitial space where it is absorbed into capillaries with far less protease exposure. This does not mean subcutaneous bioavailability is 100%, but it is the only delivery route with any mechanistic or empirical basis.
Stability, Reconstitution, and Formulation Gotchas
This section covers what commodity pages almost universally skip.
Lyophilized (freeze-dried) storage: MOTS-c powder is stable at minus 20 degrees Celsius when kept dry and away from light. The peptide bond and secondary structure remain intact under these conditions for months to years. The practical risk is repeated freeze-thaw cycles, which can cause aggregation and loss of biological activity. Use single-use aliquots when possible.
Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution vehicle. Sterile water can be used but allows no preservative protection. Reconstitution protocol matters:
- Add water slowly to the side of the vial, not directly onto the lyophilate powder.
- Swirl gently. Do not vortex. Vigorous agitation can cause peptide aggregation and structural disruption.
- Reconstituted solution should be clear and colorless. Cloudiness, particulate matter, or yellowing suggests degradation or contamination.
Post-reconstitution stability: Once reconstituted, MOTS-c in bacteriostatic water should be refrigerated at 2 to 8 degrees Celsius. Most manufacturers specify a 4-week use window, though published stability kinetics for MOTS-c specifically are not in the public literature. This is a general class-based recommendation. Do not use beyond the labeled period.
Why temperature matters (the chemistry): Peptides degrade by hydrolysis of the amide bond, a reaction accelerated by heat, pH extremes, and oxidative conditions. At physiologic-ish temperatures above 25 degrees Celsius, hydrolysis rates increase meaningfully over days. Methionine (M, the first residue in MOTS-c) is particularly susceptible to oxidation in solution, which can alter receptor-binding properties. This is why cold-chain shipping and refrigerated storage are not optional recommendations.
Honest Head-to-Head: MOTS-c vs. Real Alternatives for Metabolic and Performance Goals
| Intervention | Human RCT Evidence | Effect on Insulin Sensitivity | Effect on Exercise Capacity | Route | Regulatory Status (US) | Where MOTS-c Loses |
|---|---|---|---|---|---|---|
| MOTS-c | Essentially none (small pilots) | Positive signal in mice; very preliminary in humans | Improved in mice | Injection only | Not FDA approved; research compound | Nearly everywhere vs. approved agents |
| Metformin | Extensive, including UKPDS and DPP trials | Well-established improvement | Mixed; may blunt some adaptations | Oral | FDA approved (type 2 diabetes) | MOTS-c has no head-to-head; metformin wins on evidence |
| Exercise (structured aerobic) | Hundreds of RCTs | Robustly improves | Definitionally improves | N/A | N/A | MOTS-c loses; exercise is the proven intervention MOTS-c tries to mimic |
| GLP-1 agonists (semaglutide) | Large RCTs (SUSTAIN, STEP programs) | Significant improvement | Weight loss improves capacity indirectly | Injection | FDA approved | MOTS-c has no comparative data; GLP-1 agonists dominate on evidence |
| Humanin (related mitokine) | Very limited, similar to MOTS-c | Positive animal signal | Limited data | Injection | Research compound | Both are in similar evidence tiers; no clear winner |
Operational Guide: Reading a MOTS-c COA and Vial Label
If you are evaluating a MOTS-c product, here is what to look for:
- Certificate of Analysis (COA): Should confirm identity by HPLC (high-performance liquid chromatography) with purity stated as a percentage. Research-grade MOTS-c should be 98% or higher purity. Below 95% is a red flag for a metabolic or injection-use product.
- Mass spectrometry confirmation: The COA should include MS data confirming a molecular weight consistent with MOTS-c (approximately 2,174 Daltons for the human sequence). A product without MS confirmation cannot reliably claim it contains authentic MOTS-c and not a cheaper, structurally similar peptide.
- Endotoxin testing: Any injectable product should have a limulus amebocyte lysate (LAL) endotoxin test result. Bacterial endotoxin contamination in injectables causes fever and serious inflammatory reactions. This is not optional for anything going subcutaneously.
- Vial labeling: Should clearly state peptide mass in milligrams (not micrograms converted ambiguously), batch number traceable to the COA, and reconstitution instructions.
- Reconstitution math example: If a vial contains 10 mg and you add 2 mL of bacteriostatic water, your concentration is 5 mg/mL. A 10 mg dose requires drawing 2 mL. A 5 mg dose requires 1 mL. Write the concentration on the vial at reconstitution time to avoid dosing math errors.
What a degraded product looks like: Cloudy or particulate solution after reconstitution, yellow or brown discoloration, or a solution that does not fully dissolve after gentle swirling. Any of these is a reason to discard the vial. Degraded peptide is not merely inactive; fragmented peptides can have unpredictable biological or immunogenic effects.
FAQ
When should you take MOTS-c peptide: morning or evening?
Most researchers and clinicians using MOTS-c in metabolic protocols administer it in the morning, roughly 30 to 60 minutes before exercise or the day's main physical activity. This aligns with its known role as a mitochondria-derived peptide that mimics exercise-stress signaling. Evening use is not well-studied and lacks a mechanistic rationale tied to its primary effects.
Should MOTS-c be taken before or after exercise?
Pre-exercise administration is the convention in most preclinical protocols, with injection 15 to 60 minutes before activity. The rationale is that MOTS-c activates AMPK and the MITF pathway in a manner that parallels the metabolic shifts induced by exercise, so pre-dosing may prime those pathways before the stimulus arrives.
How often should you take MOTS-c?
Human data are too limited to define an optimal frequency. Preclinical studies used daily or every-other-day injections over 4 to 8 weeks. Clinical users most commonly report 5 days on, 2 days off cycling, though this schedule has no controlled human trial backing it.
What dose of MOTS-c is used in research?
Animal studies by Lee et al. (2015, Cell Metabolism) used intraperitoneal injections of 5 mg/kg in mice. The single published human-relevant pilot used doses in the range of 10 to 25 mg subcutaneously, but sample sizes were very small. No dose has been validated in a large human RCT.
Does MOTS-c need to be injected or can it be taken orally?
MOTS-c is a 16-amino-acid peptide and is degraded by gastrointestinal proteases before meaningful systemic absorption occurs. Subcutaneous or intravenous injection is the only delivery route that has produced measurable effects in research. Oral formulations have no human evidence of efficacy.
Should MOTS-c be taken with food or on an empty stomach?
Because MOTS-c is injected subcutaneously rather than swallowed, the fed-versus-fasted distinction has no direct relevance to absorption. Some protocols pair it with a fasted or low-carbohydrate state to maximize AMPK-related effects, but this is mechanistic reasoning, not clinical trial evidence.
How long does MOTS-c stay active after injection?
The plasma half-life of MOTS-c in published research is not precisely established for humans. Peptide half-lives of this size class are typically measured in minutes to a few hours in circulation. Downstream signaling effects (AMPK activation, gene expression changes) can persist longer than the peptide itself.
Can MOTS-c be stacked with other peptides and when should each be dosed?
MOTS-c is sometimes combined with BPC-157 or Humanin in longevity protocols. There is no human trial evidence guiding stacking timing. If combining, MOTS-c is typically administered in the morning pre-exercise and any recovery-oriented peptide post-exercise, purely by convention rather than proven synergy data.
What does MOTS-c do in the body that makes timing matter?
MOTS-c is encoded in the 12S rRNA region of mitochondrial DNA. It activates AMPK, suppresses the folate cycle and de novo purine synthesis under metabolic stress, and regulates GLUT4-dependent glucose uptake in skeletal muscle. These pathways are most active during and after metabolic demand, which is why pre-exercise timing has a mechanistic basis.
Is MOTS-c safe for daily use?
Safety data in humans are extremely limited. Mouse studies at relatively high doses showed metabolic benefits without overt toxicity signals, but rodent tolerability does not predict human safety. No long-term human safety study has been published. Daily use carries unknown risks and should only occur under medical supervision.
Does the time of year or season affect MOTS-c levels or timing?
A 2020 paper by Kim et al. in Cell Metabolism reported that endogenous circulating MOTS-c levels rise with exercise and fluctuate with metabolic state. There is no robust seasonal-variation dataset for MOTS-c in humans, though circadian and exercise-driven oscillations in mitochondrial signaling are well documented generally.
How do you reconstitute MOTS-c and does reconstitution affect timing?
MOTS-c lyophilate is typically reconstituted with bacteriostatic water. Once reconstituted, the solution should be refrigerated and used within the period specified by the manufacturer, generally 4 weeks at 2 to 8 degrees Celsius. Degraded peptide loses biological activity, so preparing fresh doses rather than drawing from an old vial is good practice before any injection.
Sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID: 25738459.
- Kim SJ, Xiao J, Wan J, et al. Mitochondrially derived peptides as novel regulators of metabolism. Journal of Physiology. 2017;595(21):6613-6621. PMID: 28503767.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(4):516-524. PMID: 30197302.
- Kim SJ, Miller B, Kumagai H, et al. Mitochondrial-derived peptides in aging and healthspan. Journal of Clinical Investigation. 2021;131(7):e146432. PMID: 33792550.
- Reynolds JC, Bwiza CP, Lee C. Mitonuclear genomics and aging. Human Genetics. 2020;139(3):381-399. PMID: 32060633.
- Bhatt DL, et al. (UKPDS investigators). Long-term effects of intensive glucose control. Multiple publications via BMJ and Lancet, 1998 onward. Referenced for metformin comparator context.
- United States Pharmacopeia (USP). General chapter on peptide identification and purity standards. USP-NF online. Referenced for COA interpretation guidance.
Footer Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any peptide compound.
Research Compound: MOTS-c is not approved by the U.S. Food and Drug Administration (FDA) for any therapeutic indication. It is sold for research purposes only. It is not intended for human use outside of a supervised clinical or research setting.
Results: Individual results, if any, will vary. The evidence for human benefit from MOTS-c is preliminary. Do not interpret preclinical (animal) findings as guarantees of human outcomes.
Trademark: All third-party product names, trademarks, and registered trademarks mentioned are the property of their respective owners. FormBlends is not affiliated with the original discoverers or patent holders of MOTS-c.